Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
7BIO
170
CHF
CHF 170.00
In stock
AG-MR-C0020-M01010 mgCHF 170.00
AG-MR-C0020-M05050 mgCHF 680.00
| Product Details | |
|---|---|
| Synonyms | 7-Bromoindirubin-3'-oxime |
| Product Type | Chemical |
| Properties | |
| Formula |
C16H10BrN3O2 |
| MW | 356.2 |
| CAS | 916440-85-2 |
| Purity Chemicals | ≥99% (NMR) |
| Appearance | Dark red solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Reconstitution | Stock solutions can be made up to 10mM in DMSO. |
| Identity | Determined by 1H-NMR. |
| InChi Key | DDLZLOKCJHBUHD-WAVHTBQISA-N |
| Smiles | O\N=C1\C(\NC2=CC=CC=C\12)=C1\C(=O)NC2=C1C=CC=C2Br |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Anticancer compound.
- Caspase-independent, non-apoptotic cell death inducer.
- ATP-competitive Flt3 inhibitor.
- Necrosis inducer.
- Aurora B and C kinase inhibitor.
- DYRK1A and DYRK 2 (Dual-specificity tyrosine phosphorylation-regulated kinase) inhibitor.
- Inflammasome activator.
Product References
- Indirubin, the red shade of indigo: L. Meijer, et al. (Editors): In «Life in Progress», Station Biologique, Roscoff, 297 pp. (2006)
- 3'-substituted 7-Halogenoindirubins, a new class of cell death inducing agents: Y. Ferandin, et al.; J. Med. Chem. 49, 4638 (2006)
- 7-Bromoindirubin-3'-oxime induces caspase-independent cell death: J. Ribas, et al.; Oncogene 25, 6304 (2008)
- Inverse in silico screening for identification of kinase inhibitor targets: S. Zahler, et al.; Chem. Biol. 14, 1207 (2007)
- An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins: V. Myrianthopoulos, et al.; J. Med. Chem. 50, 4027 (2007)
- 7-Bromoindirubin-3'-oxime uncovers a serine protease-mediated paradigm of necrotic cell death: J. Ribas, et al.; Biochem. Pharmacol. 76, 39 (2008)
- Cutting edge: Necrosis activates the NLRP3 inflammasome: H. Li, et al.; J. Immunol. 183, 1528 (2009)
- Anticancer effects and antimetastatic mechanisms of novel indirubin derivatives: C.A. Kressirer; Diss. Ludwig-Maximilians-Universitaet Munchen, (2010)
- Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells: K.A. Nicolaou, et al.; BBRC 425, 76 (2012)
- From Tyrian purple to kinase modulators: naturally halogenated indirubins and synthetic analogues: K. Vougogiannopoulou & AL. Skaltsounis; Planta Med. 78, 1518 (2012)
- A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling: L. Liu, et al.; Cancer Biol. Ther. 13, 1255 (2012)
- Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases: V. Myrianthopoulos, et al.; ACS Med. Chem. Lett. 4, 22 (2013)
Related Products
